No news is bad news for Atara
The Embold trial continues unchanged, but investors have got cold feet.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Asco 2022 – Adicet works hard to avoid the allo Car-T scenario
Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?
Asco 2022 – Carvykti casts a long shadow
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.
Sernova gets under the skin
The company believes its new combination technology can make insulin injections a thing of the past.
Iovance hammered as cell therapy disappoints
Lower – and shorter – efficacy add to serious doubts about the TIL therapy's future.
